Country’s apex biomedical research agency is also helping Zydus Cadila for laboratory assays to detect antibody response, according to documents reviewed by Mint
ICMR made a presentation before the members of the parliamentary standing committee on home affairs on Wednesday (Photo: ANI)
The Indian Council of Medical Research (ICMR) is supporting Serum Institute of India (SII) in conducting the phase 2 and 3 clinical trials for two vaccines for covid-19, one developed by University of Oxford and the other by US-based Novavax.
Country’s apex biomedical research agency is also helping Zydus Cadila for laboratory assays to detect antibody response, according to documents reviewed by Mint. The ICMR made a presentation before the members of the parliamentary standing committee on home affairs on Wednesday.
Dr Balram Bhargava, Director-General ICMR, according to sources, told the parliament panel that the vaccine candidates developed by Oxford University handled by SII are going to enter phase-2 trials by the end of this week and about 1,700 patients have been identified at 17 centres across the country for trial.
In a clinical trial, every site has a committee which monitors whether the study meets ethical guidelines and the trial protocol, without which principal investigators of that particular site cannot go ahead.
The ICMR in its presentation informed members of the committee that Bharat Biotech’s inactivated vaccine candidate, co-developed with the National Institute of Virology and Zydus Cadila Ltd’s DNA plasmid vaccine are currently in Phase 1 clinical trials.
“The ICMR is supporting both the companies in parallel pre-clinical studies of safety, immunogenicity and efficacy in non-human primates and laboratory assays for antibody detection and immunological response assessment," the ICMR presentation document stated. Meanwhile, SII is currently also undertaking a phase 3 clinical trial of Astrazeneca plc and University of Oxford’s jointly-developed adenovirus-based covid-19 vaccine.
Bhargava during the meeting indicated that an emergency authorisation could be considered for covid-19 vaccines, if the government takes a decision. However, the ICMR also hinted that it will rigorously follow the ethics and safety protocols before taking any concrete decision.
“Vaccine trials needs to follow all ethics and science required for that. Vaccine trials are in process and we can speak only when some results will be available," said Dr Rajni Kant, head, research management, policy, planning and coordination division, ICMR.
The government has already said that India is not planning to follow a pre-set benchmark for selection of a covid-19 vaccine while exploring options for mass immunisation drive for the highly infectious disease. The National Expert Group on Vaccine Administration has been constituted which has been tasked with keeping logistics, financial and other support ready when a vaccine is approved, and also selecting a suitable vaccine for mass administration.
Government officials said that they are looking at various benchmarks such as cost, ease of administration and efficacy to determine which of the vaccines that are approved can be used in a mass-immunisation drive against covid-19.
The number of covid-19 cases continue to rise in the country. India on Thursday recorded 68555 covid-19 cases taking the total tally to 2849765 and the toll rose to 54467.
The ICMR has been ramping up the covid-19 testing in the country. For the first time, a record number of more than 9 lakh covid-19 tests have been conducted in a single day on Thursday. With 9,18,470 covid-19 tests done in the last 24 hours, India is poised to see an exponential increase towards its resolve of testing 10 lakh samples daily. The cumulative tests on Thursday crossed 3.25 crore (3,26,61,252), the union health ministry said.
The Tests Per Million (TPM) have seen a sharp increase to 23668. As the national average falls below 8%, there are 26 States/UTs that are reporting lower rates than the national average.
There has been a steady rise in the national network of diagnostic labs too. With 977 labs in the government sector and 517 private labs, the lab infrastructure has been enhanced to 1494 labs today, the union health ministry said.
Source - livemint
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.